Aero-Engine industry professionals to gather in Dallas June 30-July 1 for Aviation Week Network’s Aero-Engines Americas 2021

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) — Aero-engine professionals will converge on June 30-July 1 at the Fairmont Dallas for Aviation Week Network’s Aero-Engines Americas 2021 conference to capitalize on the engine MRO market’s recovery and anticipated growth. The hybrid event will be held in-person with the option for attendees to participate virtually.

The two-day conference is exclusively dedicated to the trends and issues related to the America’s engine MRO community, gathering attendees from nearly 200 companies including airlines (Alaska Airlines, All Nippon Airways, Allegiant Airlines, Amazon Air, American Airlines, Asia Pacific Airlines, Delta Airlines, Southwest Airlines, United Airlines), MROs, OEMs, lessors and suppliers.

The event includes two days of industry expert speakers, an exhibitor showcase, two evening cocktail networking sessions, lunches and coffee breaks. For a full agenda and list of speakers see here and to register see here.

“Aero-Engines Americas’ role as the premier conference for the region’s engine community is more important than ever, providing a forum to reconnect safely and plan the recovery,” said Lydia Janow, Managing Director of Events for Aviation Week Network. “Attendees have the opportunity to access the knowledge they need to help rebuild and restore the engine industry. Our agenda has been created from critical research we have conducted with past speakers, attendees, and other industry experts.”

Exclusively for Aero-Engines Americas attendees, BP Aero will host a shop tour of its facilities located near the DFW airport on the afternoon of Thursday, July 1. BP Aero is a full service aviation solutions provider specializing in engine teardown, engine part overhaul, accessory overhaul, lease returns and engine hospital shop repairs.

Aero-Engines Americas 2021 Host Sponsor is BP Aero with Engine Lease FinanceLockheed Martin Engine SolutionsRamco, and StandardAero serving as event sponsors.

Aviation Week Network is the largest multimedia information and services provider for the global aviation, aerospace, and defense industries, serving 1.7 million professionals around the world. Industry professionals rely on Aviation Week Network to help them understand the market, make decisions, predict trends, and connect with people and business opportunities. Customers include the world’s leading aerospace manufacturers and suppliers, airlines, airports, business aviation operators, militaries, governments and other organizations that serve this worldwide marketplace. Aviation Week Network’s portfolio delivers award-winning journalism, data, intelligence and analytical resources, world-class tradeshows and conferences, and results-driven marketing services and advertising is helping our customers succeed. Aviation Week Network is part of Informa Markets, a division of Informa PLC.

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit

Elizabeth Kelley Grace

Ocean Biomedical, Inc. Files Registration Statement For Proposed Initial Public Offering

PROVIDENCE, R.I., June 10, 2021 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (“Ocean”) today announced that it has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of shares of its common stock. Ocean intends to list its common stock on the Nasdaq Global Market under the symbol “OCEA.” The size of the proposed offering and price range for the proposed offering have not yet been determined.

It is expected that the net proceeds from Ocean’s initial public offering will be used to fund the clinical development and preclinical development of Ocean’s assets, and for business development activities, working capital and other general corporate purposes.

Berenberg and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. LifeSci Capital, Ladenburg Thalmann, Brookline Capital Markets and Roth Capital Partners are acting as co-managers for the offering.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from: Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at, or Oppenheimer & Co. Inc., Attn: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by calling (212) 667-8055, or by emailing

The Registration Statement has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.

This press release is being made pursuant to, and in accordance with, Rule 134 under the Securities Act of 1933, as amended (the “Securities Act”), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Forward-Looking Statements

This release may contain certain forward-looking statements relating to us and our business which involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “proposed” and “expect” or similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the proposed initial public offering, including the size of such offering, the plan to list on the Nasdaq Global Market, the expected timing of such initial public offering and the expected use of proceeds from such initial public offering. The forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecast in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to uncertainties related to market conditions and the SEC’s review process, and other factors relating to our business described in the section entitled “Risk Factors” in the Registration Statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date of this release. The factors described therein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could affect our forward-looking statements. Consequently, our actual performance could be materially different from the results described or anticipated by our forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by the federal securities laws, we undertake no obligation to update any forward-looking statements.

SOURCE Ocean Biomedical, Inc.

Kevin Kertscher
Communications Director
Ocean Biomedical 
(401) 642-6322

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

–Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies–
–Laura Shawver, Christine Siu join as independent directors–

BASEL, Switzerland and SAN DIEGO, Calif., June 10, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing. The round was led by RA Capital, with participation by founding investor Versant Ventures and new investors Fidelity Management & Research Company, Invus, Qatar Investment Authority, funds and accounts managed by BlackRock, Alexandria Venture Investments and an undisclosed leading healthcare investment fund.

Bright Peak uses a novel technology to chemically synthesize therapeutic cytokines by ligating together customized peptide segments. This proprietary technology provides unique flexibility to both tune and enhance cytokine biology through affinity modification and orthogonal, site-specific conjugation. The company’s platform also allows for the conjugation of its enhanced cytokines as payloads to certain antibodies, creating novel and proprietary “Bright Peak Immunocytokines.” These Immunocytokines will allow tissue- and cell-specific targeting of the cytokine payload with the added potential for synergistic efficacy through potency-enhancing avidity effects.

“The investment from this accomplished crossover syndicate underscores the enthusiasm for our platform and re-affirms our commitment to transform the therapeutic utility of cytokines to treat people with cancer and autoimmune diseases,” said Fredrik Wiklund, president and CEO of Bright Peak. “This capital will allow us to expand our Immunocytokine platform and advance our deep pipeline of programs across IL-2, IL-18 and IL-7.”

Also today, Bright Peak announced key additions to its board of directors with the appointments of independent directors Laura Shawver, Ph.D., and Christine Siu. Dr. Shawver, currently CEO of Silverback Therapeutics, is an industry veteran with an extensive scientific, translational and clinical background as well as a broad range of strategic expertise. Most recently, she was president and CEO of Synthorx, a developer of engineered cytokines for cancer and autoimmune disorders that was acquired by Sanofi in 2020 for $2.5 billion. She received her Ph.D. in pharmacology from the University of Iowa.

Ms. Siu is the chief operating officer in-residence at BridgeBio Pharma Inc., and former CFO at Eidos Therapeutics Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. Prior to that, she was the CBO at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT), and before that, a venture principal at Third Rock Ventures. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.

On the Bright Peak board, Dr. Shawver and Ms. Siu join RA Capital’s Josh Resnick, M.D., and Michael Rosenzweig DVM, Ph.D., who joined in connection with the Series B financing, as well as existing board members Alex Mayweg, Ph.D., and Tom Woiwode, Ph.D., of Versant Ventures.

“We are pleased to lead a financing that will enable Bright Peak to broadly invest in its platform technologies, development programs, people, and, ultimately, towards delivering a pioneering new category of cytokine immunotherapies to patients in need,” said Dr. Resnick.

“We warmly welcome Laura, Christine, Josh, and Michael to our Board of Directors. Their deep domain expertise and business acumen will serve as a tremendous resource to the Company,” said Dr. Mayweg.

About Bright Peak

Bright Peak is a privately held biotechnology company based in San Diego, CA and Basel, Switzerland developing innovative cytokine therapeutics that are uniquely engineered to precisely tune and control desired biological properties. Using its proprietary Enhanced Design and Combine (EDC) chemistry platform, Bright Peak is developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases. Bright Peak is also pioneering a new category of “Bright Peak Immunocytokines” that simultaneously leverages the precision of antibody targeting with cytokine-mediated selective immune modulation in the desired microenvironment.


Zoom เปิดตัว Zoom Phone Appliances เพื่อเสริมศักยภาพพนักงานที่ทำงานแบบผสมผสาน

Zoom Phone Appliances มอบโซลูชันโทรศัพท์ตั้งโต๊ะแบบครบวงจรสำหรับการโทรและการประชุม ด้วยโซลูชันฮาร์ดแวร์จาก Poly และ Yealink

ซานโฮเซ่, แคลิฟอร์เนีย, June 10, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) วันนี้ได้ประกาศเปิดตัว Zoom Phone Appliances ซึ่งเป็นฮาร์ดแวร์ประเภทใหม่ที่ได้รับการปรับแต่งสำหรับพนักงานที่ทำงานแบบผสมผสาน ตั้งแต่โฮมออฟฟิศไปจนถึงพื้นที่ประชุมเล็กๆ ที่ใช้ร่วมกัน เพื่อรับมือกับรูปแบบการใช้งานในอุตสาหกรรมต่างๆ Zoom Phone Appliances ผสานรวมเทคโนโลยี Zoom เข้ากับฮาร์ดแวร์จาก Poly และ Yealink เพื่อมอบความสามารถด้านวิดีโอและเสียงและจอสัมผัส ในโซลูชันโทรศัพท์ตั้งโต๊ะแบบครบวงจรสำหรับการประชุมทางวิดีโอความละเอียดสูง การโทรศัพท์ และกระดานอัจฉริยะ

“Zoom ยังคงแสดงให้เห็นถึงความก้าวหน้าอย่างรวดเร็วของนวัตกรรมและความสามารถในการขยายตัวไปทั่วโลกด้วยโทรศัพท์ระบบคลาวด์ที่แข็งแกร่งของบริษัท Zoom Phone” Elka Popova รองประธานฝ่ายวิจัยงานเชื่อมต่อที่ Frost & Sullivan กล่าว “Zoom Phone เป็นทางเลือกใหม่สำหรับโซลูชันโทรศัพท์รุ่นเก่าเสมอมา และโปรแกรมอุปกรณ์ใหม่นี้จะช่วยเพิ่มคุณค่าที่ส่งมอบให้ลูกค้าของเราโดยการทำให้ธุรกิจต่างๆ เปิดใช้งานพื้นที่ทำงานทางวิดีโอด้วยอุปกรณ์ที่สร้างขึ้นโดยมีวัตถุประสงค์เฉพาะซึ่งง่ายต่อการจัดหา ใช้งาน และจัดการ”

“สถานที่ทำงานแบบดั้งเดิมกำลังพัฒนาและเปลี่ยนแปลง และเป้าหมายของเราคือการเพิ่มขีดความสามารถให้พนักงานทำได้หลายอย่างมากขึ้น โดยทำให้เส้นกั้นบางๆ ระหว่างการใช้งานเสียงและวิดีโอหายไป” Graeme Geddes หัวหน้าแผนก Zoom Phone และ Zoom Rooms ที่ Zoom กล่าว “โปรแกรม Zoom Phone Appliance ใหม่มาพร้อมฮาร์ดแวร์ Zoom Phone ที่ออกแบบมาเพื่อวัตถุประสงค์เฉพาะจาก Poly และ Yealink ช่วยปรับปรุงประสิทธิภาพการสื่อสาร ขจัดความยุ่งเหยิง และมอบประสบการณ์การสื่อสารที่ทรงพลัง”

Zoom Phone Appliances ช่วยลดความยุ่งยากในการออกใบอนุญาต การติดตั้ง การใช้งาน และการจัดการ ซึ่งเป็นประโยชน์ต่อทั้งผู้ใช้ปลายทางและแผนกไอที จุดเด่นเพิ่มเติมของ Zoom Phone Appliances ประกอบด้วย:

  • โทรศัพท์ตั้งโต๊ะที่มีคุณสมบัติครบถ้วนพร้อมความสามารถของ Zoom อันทรงพลัง Zoom Phone Appliances เปิดใช้งานอยู่เสมอ และพร้อมสำหรับการสื่อสารและการทำงานร่วมกันในทันที เริ่มการประชุมเฉพาะกิจหรือตามกำหนดเวลา โทรออกและรับสาย ตรวจสอบข้อความเสียง และทำงานร่วมกันแบบเสมือนด้วยการแบ่งปันเนื้อหาและคำอธิบายประกอบได้อย่างง่ายดาย
  • การจัดการแบบรวมศูนย์ผ่าน Zoom Admin Portal: การจัดการแบบรวมศูนย์ที่ง่ายขึ้น ปรับขนาดได้พร้อมการจัดเตรียมและการอัปเดตจากระยะไกล
  • ไม่ต้องมีใบอนุญาตเพิ่มเติม: เข้าสู่ระบบ Zoom Phone Appliance ด้วยบัญชี Zoom ของคุณ และสร้างประสบการณ์การใช้งานสำนักงานแบบทันที
  • ปรับแต่งตามความต้องการสำหรับผู้ใช้: ซิงค์กับปฏิทินผู้ใช้ สถานะ การตั้งค่าการประชุม และโทรศัพท์เพื่อประสบการณ์การสื่อสารแบบรวมศูนย์ที่เน้นวิดีโอเป็นหลัก
  • การเริ่มต้นใช้งานที่ง่ายขึ้นด้วยการจัดเตรียมอุปกรณ์พร้อมใช้แบบไม่ต้องสัมผัส: ลดความจำเป็นในการสนับสนุนด้านไอทีด้วยการตั้งค่าและประสบการณ์ผู้ใช้ที่ง่ายขึ้น
  • จอสัมผัสพร้อมกระดานอัจฉริยะ: ทำงานร่วมกับเพื่อนร่วมงานด้วยกระดานอัจฉริยะที่สามารถส่งออกและแบ่งปันได้อย่างง่ายดาย
  • ผ่านการรับรองจาก Zoom: Zoom Phone Appliances มาพร้อมกับฮาร์ดแวร์ใหม่ที่ผ่านการรับรอง เพื่อให้มั่นใจว่าอุปกรณ์เหล่านี้สร้างขึ้นตามวัตถุประสงค์เพื่อประสบการณ์การใช้งาน Zoom Phone และการประชุมที่เหมาะสมที่สุด อุปกรณ์อื่นๆ จะนำเพิ่มในหมวดหมู่นี้เมื่อเวลาผ่านไป

การเปิดตัวของ Zoom Phone Appliances นำเสนอโซลูชันอันล้ำสมัยจากพันธมิตรฮาร์ดแวร์ของ Zoom สองราย ได้แก่ Poly และ Yealink และรายอื่นๆ ในอนาคต

Poly CCX 600 Desk Phone และ CCX 700 Desk Phone ที่มาพร้อมกล้องวิดีโอในตัว

“เรารู้สึกตื่นเต้นที่ได้เป็นหนึ่งในพันธมิตรรายแรกๆ ที่ผสานรวมประสบการณ์ใช้งาน Zoom แบบเนทีฟเข้ากับตระกูล Poly CCX ของเรา ดั่งเช่น Zoom Phone Appliances” John Lamarque รองประธานและผู้จัดการทั่วไปด้านการทำงานร่วมกันผ่านเสียงของ Poly กล่าว “สิ่งนี้นำแพลตฟอร์ม Zoom ที่เราทุกคนรู้จักและชื่นชอบมาสู่หน้าจอระบบสัมผัสของอุปกรณ์ มอบประสบการณ์ที่ทรงพลังและน่าตื่นตาตื่นใจ”

Yealink VP59 Smart Video Phone

“เรามีความยินดีที่จะเปิดตัว Zoom Phone Appliance วิดีโอโฟน VP59 รุ่นใหม่ที่ไว้วางใจได้และล้ำสมัย” Alvin Liao รองประธานฝ่ายผลิตภัณฑ์ที่ Yealink กล่าว “หน้าจอสัมผัสของวิดีโอโฟน VP59 จะใช้แพลตฟอร์มการสื่อสารผ่านวิดีโอระดับแถวหน้าในอุตสาหกรรมของ Zoom มอบอินเทอร์เฟซที่ใช้งานง่ายและประสบการณ์การใช้งานที่ง่ายดายให้กับลูกค้า”

Zoom Phone Appliances มีให้บริการผ่านโปรแกรม Zoom Hardware-as-a-Service และจากตัวแทนจำหน่าย Poly และ Yealink ที่ได้รับอนุญาต หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับ Zoom Phone Appliances โปรดไปที่เว็บไซต์ Zoom Phone Appliances และอ่านบล็อกของเรา

เกี่ยวกับ Zoom
Zoom คือสิ่งที่สร้างมาเพื่อคุณ เราช่วยให้คุณแสดงความคิด เชื่อมต่อกับผู้อื่น และต่อยอดไปสู่อนาคตที่ถูกจำกัดเพียงจินตนาการของคุณ แพลตฟอร์มการสื่อสารที่ราบรื่นของเราเป็นเพียงแพลตฟอร์มเดียวที่เริ่มต้นด้วยการมีวิดีโอเป็นรากฐาน และเราได้ตั้งมาตรฐานสำหรับนวัตกรรมนับตั้งแต่นั้นเป็นต้นมา เราจึงเป็นตัวเลือกที่ใช้งานง่าย ปรับขนาดได้ และปลอดภัยสำหรับทั้งบุคคล ธุรกิจขนาดเล็ก และองค์กรขนาดใหญ่ Zoom ก่อตั้งขึ้นในปี 2011 มีการซื้อขายต่อสาธารณะ (NASDAQ:ZM) และมีสำนักงานใหญ่ในซานโฮเซ่ รัฐแคลิฟอร์เนีย เยี่ยมชม และติดตาม @zoom

ฝ่ายประชาสัมพันธ์ Zoom
Farshad Hashmatulla
Product PR Manager

Virtusa Appoints Santosh Thomas as Chief Executive Officer

SOUTHBOROUGH, Mass., June 09, 2021 (GLOBE NEWSWIRE) — Virtusa Corporation, a global provider of digital strategy, digital engineering and IT services and solutions that help clients change and disrupt markets through innovation engineering, today announced the appointment of Santosh Thomas as its new Chief Executive Officer (CEO).

Virtusa’s Board of Directors appointed Santosh as successor to the company’s founder, Kris Canekeratne, who announced his transition from the business in May 2021. Santosh joins Virtusa during a time of significant growth and follows the recent appointment of Sander van‘t Noordende to the position of Chairman of the Board of Directors.

Santosh brings more than 20 years of leadership and industry experience to Virtusa. Most recently Santosh served as President of Global Growth Markets at Cognizant where he managed a business with revenues over $4 billion and built multiple billion-dollar businesses in Europe and Asia Pacific in Banking, CommTech and Products & Resources. In his new role, Santosh will help Virtusa drive growth in key markets and continue to be recognized as an employer of choice.

“On behalf of the entire company and the Board of Directors, I would like to thank Kris for his more than two decades of leadership,” said Sander van‘t Noordende. “I would also like to welcome Santosh who brings a stellar track record of client service, leadership, and proven success. Santosh has the vision and experience to take Virtusa’s deep heritage in digital engineering to new levels of growth.”

“I am deeply honored to join Virtusa at this exciting time for our employees, clients and partners,” said Santosh Thomas. “I have admired Kris and Virtusa for fostering a culture of innovation and distinguishing itself as a global leader in helping customers tackle their unique digital transformation challenges. Virtusa has a great brand reputation, an impressive roster of strategic partners, and is well positioned for sustained growth.”

“When I founded Virtusa 25 years ago I had a vision to build a global powerhouse in digital engineering services. And we did just that,” said Kris Canekeratne. “I leave with the confidence that the company and its leadership team have never been stronger and its opportunities have never been greater. I welcome Santosh Thomas to the CEO role and wish him the best in his efforts to lead Virtusa through its next phase of growth.”

Also announced today, Denise Warren has joined Virtusa’s Board of Directors and has been appointed Chairperson of its Audit Committee. Ms. Warren recently retired from her position as Chief Operating Officer (COO) of WakeMed Health & Hospitals, and serves on the boards of Brookdale Senior Living, Computer Programs & Systems Inc., and Rockroom Insurance Group.

About Virtusa

Virtusa Corporation is a global provider of digital business strategy, digital engineering, and information technology (IT) services and solutions that help clients change, disrupt, and unlock new value through innovative engineering. Virtusa serves Global 2000 companies in Banking, Financial Services, Insurance, Healthcare, Communications, Media, Entertainment, Travel, Manufacturing, and Technology industries.

Virtusa helps clients grow their business with innovative products and services that create operational efficiency using digital labor, future-proof operational and IT platforms, and rationalization and modernization of IT applications infrastructure. This is achieved through a unique approach blending deep contextual expertise, empowered agile teams, and measurably better engineering to create holistic solutions that drive the business forward at unparalleled velocity enabled by a culture of cooperative disruption.

Virtusa is a registered trademark of Virtusa Corporation. All other company and brand names may be trademarks or service marks of their respective holders.

Media Contact:

Matt Berry
Conversion Marketing
(201) 370-9133

Amlan Invests in Growing Animal Protein Market in China With Technical Staff Additions and Logistics Expansion

Amlan Adds to Team in China

Michael Hua (top), Regional Technical Service Manager, and King Zhu (bottom), Technical Service Manager, Amlan International.

CHICAGO, June 09, 2021 (GLOBE NEWSWIRE) — A growing market for animal protein in China is motivating poultry and pork producers to rapidly adopt natural technology advancements to meet growing demand while addressing increasing production challenges. Amlan International, a global leader in mineral-based feed additives that promote the optimal intestinal health of poultry and livestock and improve the economics of production, is helping producers meet those challenges with the addition of experienced technical professionals and the expansion of its logistics operations throughout the country.

Amlan recently appointed eight sales, marketing and technical employees to its staff in China. They include Michael Hua, Regional Technical Service Manager, and King Zhu, Technical Service Manager. As a team lead, Hua will support and coach the sales team and channel partners to successfully build and expand the local technical service experience. Zhu joins Hua’s technical service team and brings years of experience in swine production.

“China is the world’s largest producer of pork and the top three in poultry production, and operations continue to grow in the country. We’re committed to bringing the resources and expertise needed to help producers rise to the challenge to meet growing demand and evolving customer preferences,” says Fred Kao, Amlan’s Vice President of Global Sales.

Amlan has also invested in expanding the capabilities of its three logistics centers, located strategically within China to meet the increased demand. Amlan established its China subsidiary, Amlan Trading (Shenzhen) Company, Ltd., in 2013 and since added logistic warehouses in Tianjin, northeast China; Shenzhen in the southeast; and Chongqing in the southwest. The supply hubs allow Amlan to quickly adjust to shifting product demands within the country.

“The size of China’s consumer base and its rising middle class are contributing to an increased demand in animal protein in that market. The strategic new hires and investment in our infrastructure in China help support our mission of providing excellence in technical and customer service to keep pace with the growth of the business and evolving regulations,” says Harold Zhou, Director of Operations for China, Amlan International. “Amlan’s advancements in feed additive research and formulation are helping to transform animal protein production by providing proven and reliable alternatives to in-feed antibiotics used to promote growth and productivity in poultry and swine production.”

The additional team members will provide enhanced knowledge and service for customers across the country. In addition to Hua and Zhu, Amlan also recently added the following to the China team:

  • Teng Yingyun, Area Sales Manager, General South of China. Teng has 15 years of experience at another leading animal health company.
  • Chen Yazhou, Sales Manager. He brings 10-plus years of sales experience to Amlan to support poultry and swine customers.
  • Luo Qiong, Sales Manager. Lou spent years at a top animal health company working as a technical representative where he managed key customer relationships.
  • Sissi Fang, Senior Marketing Specialist. Sissi was a member of a top animal health company for seven years, where she built experience in marketing communications.
  • Coy Xiao, HR and Paralegal Manager. Coy brings years of leading human resource efforts for various companies.
  • Jane Yang, Finance Manager. Using her extensive financial background, Jane will work to further support Amlan’s business expansion in China.

Company Information
Amlan International offers mineral-based feed additives to poultry and livestock producers. Amlan is the animal health business of Oil-Dri Corporation of America, leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact

A photo accompanying this announcement is available at